Updated Clinical Perspectives and Challenges of Chimeric Antigen Receptor-T Cell Therapy in Colorectal Cancer and Invasive Breast Cancer

Cao, Yu; Efetov, Sergey; He, Mingze; Fu, Yu; Beeraka, Narasimha M; Zhang, Jin; Zhang, Xinliang; Bannimath, Namitha; Chen, Kuo

doi:10.1007/s00005-023-00684-x

Cited by 9 publications

(8 citation statements)

References 176 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, CD44 isoforms have been found as an promising target for chimeric antigen receptor T cells (CAR T cells) to eliminate CD44 expressing cancer, which is a novel and specific treatment. 277 , 278 CD44v6 is found to be associated with tumor progression and aggressive behavior. 279 Hence, CD44v6 CAR T cells is an attractive therapy to control tumor growth.…”

Section: Anticancer Therapeutic Strategies Based On Targeting Cd44mentioning

confidence: 99%

CD44 and its implication in neoplastic diseases

Xu,

Bai,

Lan

et al. 2024

MedComm

View full text Add to dashboard Cite

CD44, a nonkinase single span transmembrane glycoprotein, is a major cell surface receptor for many other extracellular matrix components as well as classic markers of cancer stem cells and immune cells. Through alternative splicing of CD44 gene, CD44 is divided into two isoforms, the standard isoform of CD44 (CD44s) and the variant isoform of CD44 (CD44v). Different isoforms of CD44 participate in regulating various signaling pathways, modulating cancer proliferation, invasion, metastasis, and drug resistance, with its aberrant expression and dysregulation contributing to tumor initiation and progression. However, CD44s and CD44v play overlapping or contradictory roles in tumor initiation and progression, which is not fully understood. Herein, we discuss the present understanding of the functional and structural roles of CD44 in the pathogenic mechanism of multiple cancers. The regulation functions of CD44 in cancers‐associated signaling pathways is summarized. Moreover, we provide an overview of the anticancer therapeutic strategies that targeting CD44 and preclinical and clinical trials evaluating the pharmacokinetics, efficacy, and drug‐related toxicity about CD44‐targeted therapies. This review provides up‐to‐date information about the roles of CD44 in neoplastic diseases, which may open new perspectives in the field of cancer treatment through targeting CD44.

show abstract

Section: Anticancer Therapeutic Strategies Based On Targeting Cd44mentioning

confidence: 99%

CD44 and its implication in neoplastic diseases

Xu,

Bai,

Lan

et al. 2024

MedComm

View full text Add to dashboard Cite

show abstract

“…CAR is an artificial receptor molecule created by genetic engineering technology that confers specificity to immune effector cells against a target antigenic epitope, thereby enhancing T‐lymphocyte recognition of antigenic signals and activation. 18 The CAR structure consists of an extracellular binding region that is usually the single‐chain fragment variable (scFv) region, a hinge, a transmembrane domain, and an intracellular signalling domain. 19 , 20 A typical intracellular signalling region contains a CD3 activation domain and a co‐stimulatory proliferative signalling domain.…”

Section: Structure Of Carmentioning

confidence: 99%

Recent advances in CAR‐T cell therapy for acute myeloid leukaemia

Gao,

Li,

et al. 2024

J Cellular Molecular Medi

View full text Add to dashboard Cite

Acute myeloid leukaemia (AML) is a fatal and refractory haematologic cancer that primarily affects adults. It interferes with bone marrow cell proliferation. Patients have a 5 years survival rate of less than 30% despite the availability of several treatments, including chemotherapy, allogeneic haematopoietic stem cell transplantation (Allo‐HSCT), and receptor antagonist drugs. Allo‐HSCT is the mainstay of acute myeloid leukaemia treatment. Although it does work, there are severe side effects, such as graft‐versus‐host disease (GVHD). In recent years, chimeric antigen receptor (CAR)‐T cell therapies have made significant progress in the treatment of cancer. These engineered T cells can locate and recognize tumour cells in vivo and release a large number of effectors through immune action to effectively kill tumour cells. CAR‐T cells are among the most effective cancer treatments because of this property. CAR‐T cells have demonstrated positive therapeutic results in the treatment of acute myeloid leukaemia, according to numerous clinical investigations. This review highlights recent progress in new targets for AML immunotherapy, and the limitations, and difficulties of CAR‐T therapy for AML.

show abstract

“…Notably, China’s malignant tumor incidence ranked second globally. It is estimated that there will be a 57.5% increase in 2040 compared to that in 2020, and the most common malignant tumors are solid tumors such as lung cancer, colorectal cancer, liver cancer, and gastric cancer [ 2 , 3 ]. Conventional chemotherapy remains the principal treatment modality for these malignancies [ 4 – 6 ].…”

Section: Introductionmentioning

confidence: 99%

Clinical research progress of callisperes® of drug-loaded microsphere arterial chemoembolisation in the treatment of solid tumors

Wang,

Zhu,

Sheng

2024

Discov Onc

View full text Add to dashboard Cite

The incidence and mortality of cancer is ever-increasing, which poses a significant challengesto human health and a substantial economic burden to patients. At present, chemotherapy is still a primary treatment for various cancers. However, chemotherapy kills tumors but also induces the related side effects, whichadversely impacting patient quality of life and exacerbating suffering. Therefore, there is an urgent need for new and effective treatments that can control tumor growth while reducing the side effects for patients. Arterial chemoembolization has been attracted much attentionwhich attributed to the advantage of ability to embolize tumor vessels to block blood and nutrition supplies. Thus, to achieve local tumor control, it has become an effective means of local tumor control and has been widely used in clinical practice. Despite its efficacy, conventional arterial chemoembolization techniques, limited by embolization materials, have been associated with incomplete embolization and suboptimal drug delivery outcomes. Gradually, researchers have shifted their attention to a new type of embolic material called CalliSperes® drug-eluting embolic bead (DEB). DEB can not only load high doses of drugs, but also has strong sustained drug release ability and good biocompatibility. The integration of DEBs with traditional arterial chemoembolization (DEB-TACE) promises targeted vascular embolization, mitigated tumor ischemia and hypoxia, and direct intravascular chemotherapy delivery. It can prevent cancer cell differentiation and accelerate their death, meanwhile, directly injecting chemotherapy drugs into the target blood vessels reduced the blood concentration of the whole body, thus reduced the toxic and side effects of chemotherapy. Furthermore, DEB-TACE's sustained drug release capability elevates local drug concentrations at the tumor site, amplifying its antitumor efficacy. Therefore, DEB-TACE has become a hot spot in clinical research worldwide. This review introduces the pathogenesis of solid tumors, the background of research and biological characteristics of DEB, and the action mechanism of DEB-TACE, as well as its clinical research in various solid tumors and future prospects. This review aims to provide new ideas for the treatment of DEB-TACE in various solid tumors.

show abstract

Updated Clinical Perspectives and Challenges of Chimeric Antigen Receptor-T Cell Therapy in Colorectal Cancer and Invasive Breast Cancer

Cited by 9 publications

References 176 publications

CD44 and its implication in neoplastic diseases

CD44 and its implication in neoplastic diseases

Recent advances in CAR‐T cell therapy for acute myeloid leukaemia

Clinical research progress of callisperes® of drug-loaded microsphere arterial chemoembolisation in the treatment of solid tumors

Contact Info

Product

Resources

About